Mutations of Janus kinase 2 (JAK2), predominantly JAK2V617F, are discovered in ~95% of patients with polycythemia vera and 50–60% of patients with essential thrombocythemia, as well as primary myelofibrosis (MF) [3–6]. The gene discussed is JAK2; the disease is primary myelofibrosis.